67.81
price up icon1.50%   0.915
 
loading
Astrazeneca PLC stock is traded at $67.81, with a volume of 1.24M. It is up +1.50% in the last 24 hours and down -9.37% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$66.90
Open:
$66.95
24h Volume:
1.24M
Relative Volume:
0.23
Market Cap:
$210.86B
Revenue:
$54.07B
Net Income/Loss:
$7.04B
P/E Ratio:
30.07
EPS:
2.255
Net Cash Flow:
$7.28B
1W Performance:
+0.05%
1M Performance:
-9.37%
6M Performance:
-12.18%
1Y Performance:
-3.17%
1-Day Range:
Value
$66.87
$67.94
1-Week Range:
Value
$66.59
$68.17
52-Week Range:
Value
$61.24
$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name
Name
Astrazeneca PLC
Name
Phone
44 20 3749 5000
Name
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Employee
61,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
67.83 210.86B 54.07B 7.04B 7.28B 2.255

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Initiated Exane BNP Paribas Outperform
Feb-13-25 Upgrade UBS Neutral → Buy
Feb-12-25 Initiated Morgan Stanley Overweight
Nov-20-24 Upgrade UBS Sell → Neutral
Nov-06-24 Upgrade Deutsche Bank Sell → Hold
Sep-13-24 Downgrade Deutsche Bank Hold → Sell
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca PLC Stock (AZN) Latest News

pulisher
07:19 AM

astrazeneca reports breakthrough in breast cancer treatment By Investing.com - Investing.com India

07:19 AM
pulisher
06:50 AM

astrazeneca reports breakthrough in breast cancer treatment - Investing.com

06:50 AM
pulisher
04:40 AM

AstraZeneca: positive results in breast cancer - marketscreener.com

04:40 AM
pulisher
02:31 AM

AstraZeneca Plc Enhertu trial hits key PFS goal - DirectorsTalk Interviews

02:31 AM
pulisher
02:29 AM

AstraZeneca reports best trial results in a decade for metastatic breast cancer treatment - Proactive Investors

02:29 AM
pulisher
Apr 21, 2025

Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight - GlobeNewswire Inc.

Apr 21, 2025
pulisher
Apr 21, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 21, 2025
pulisher
Apr 21, 2025

Omeprazole Market Is Booming Worldwide 2025-2032 | Astrazeneca Plc., Sandoz, Inc., Mylan N.V. - openPR.com

Apr 21, 2025
pulisher
Apr 21, 2025

Should You Buy, Sell Or Hold AstraZeneca Stock Before Q1 Earnings? - Barchart.com

Apr 21, 2025
pulisher
Apr 21, 2025

AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial - Seeking Alpha

Apr 21, 2025
pulisher
Apr 21, 2025

Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? - Yahoo

Apr 21, 2025
pulisher
Apr 21, 2025

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients - Yahoo Finance

Apr 21, 2025
pulisher
Apr 21, 2025

ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival Versus. THP As 1st-Line Therapy For Patients With HER2+ Metastatic Breast Cancer - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

AstraZeneca (AZN) Highlights Promising Trial Results for Enhertu in Breast Cancer Treatment | AZN Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

AstraZeneca Touts Positive Survival Data for Enhertu Combo in Broad Breast Cancer Population - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Shows High-level Results in Late-stage Trial - marketscreener.com

Apr 21, 2025
pulisher
Apr 18, 2025

Vasculitis Market Overall Study Report 2025-2032 | AstraZeneca - openPR.com

Apr 18, 2025
pulisher
Apr 17, 2025

AstraZeneca Unit Hit With Antitrust Suit Over Soliris - Law360

Apr 17, 2025
pulisher
Apr 17, 2025

AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly - Bloomberg Law News

Apr 17, 2025
pulisher
Apr 17, 2025

AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris - Reuters

Apr 17, 2025
pulisher
Apr 17, 2025

AstraZeneca Unit Faces US Class Action Lawsuit Alleging Misuse of Soliris Patent - marketscreener.com

Apr 17, 2025
pulisher
Apr 16, 2025

AstraZeneca Gets Backing to Trim Fired Worker’s Vaccine Bias Row - Bloomberg Law News

Apr 16, 2025
pulisher
Apr 16, 2025

BNP Paribas Exane sets AstraZeneca stock to outperform, PT at GBP115 - Investing.com UK

Apr 16, 2025
pulisher
Apr 15, 2025

Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

European pharma companies issue demands to stay in EU ahead of expected US tariffs - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly - insights.citeline.com

Apr 15, 2025
pulisher
Apr 15, 2025

AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib - Medical Dialogues

Apr 15, 2025
pulisher
Apr 14, 2025

Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires? - Yahoo Finance

Apr 14, 2025
pulisher
Apr 14, 2025

The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Nasdaq

Apr 14, 2025
pulisher
Apr 13, 2025

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

Apr 13, 2025
pulisher
Apr 12, 2025

AstraZeneca : India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output - marketscreener.com

Apr 12, 2025
pulisher
Apr 11, 2025

NICE recommends new combination breast cancer drug - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

astrazeneca shareholders approve all resolutions at agm - Investing.com

Apr 11, 2025
pulisher
Apr 11, 2025

Astrazeneca PLC Says All Resolutions Passed At AGM - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

AstraZeneca’s AGM Approves All Resolutions, Marks Board Changes - TipRanks

Apr 11, 2025
pulisher
Apr 11, 2025

Drug Tariffs Will Harm Patients, AstraZeneca Chairman Says - Bloomberg.com

Apr 11, 2025
pulisher
Apr 10, 2025

AstraZeneca (AZN) Gains Momentum with EU Drug Approvals - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle - Proactive financial news

Apr 10, 2025
pulisher
Apr 10, 2025

AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that - Proactive Investors

Apr 10, 2025
pulisher
Apr 10, 2025

GLP-1 Market Top PlayersAstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech. - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now? - Yahoo

Apr 10, 2025
pulisher
Apr 10, 2025

AstraZeneca (AZN) Gains EU Nod for Imfinzi Combo in NSCLC Treatm - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

AstraZeneca (AZN) Gains EU Approval for Expanded Enhertu Use in Breast Cancer - GuruFocus

Apr 10, 2025
pulisher
Apr 09, 2025

AstraZeneca Settles Covid-Shot Suit With Christian Salesman - Bloomberg Law News

Apr 09, 2025
pulisher
Apr 09, 2025

AstraZeneca Blocks Generics Ahead Of Patent Dispute - Law360

Apr 09, 2025
pulisher
Apr 09, 2025

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - Mitrade

Apr 09, 2025
pulisher
Apr 09, 2025

AstraZeneca stock touches 52-week low at $61.76 - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

AstraZeneca stock touches 52-week low at $61.76 By Investing.com - Investing.com India

Apr 09, 2025
pulisher
Apr 09, 2025

UK Regulator Approves Expanded Use of AstraZeneca's Targeted Cancer Therapy - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

UK Approves Indication Extension for AstraZeneca-Daiichi Sankyo's Cancer Drug Enhertu - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Barclays Keeps AstraZeneca at Overweight on Potential to Withstand Tariff Storm - MarketScreener

Apr 09, 2025

Astrazeneca PLC Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
Cap:     |  Volume (24h):